INJECTAPAP
Clinical safety rating
cautionComprehensive clinical and safety monograph for INJECTAPAP (INJECTAPAP).
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
| Metabolism | Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione. |
| Excretion | Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%). |
| Half-life | 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment. |
| Protein binding | 10-25% bound to albumin at therapeutic concentrations. |
| Volume of Distribution | 0.8-1.0 L/kg; suggests distribution into total body water. |
| Bioavailability | IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%. |
| Onset of Action | IV: 5-10 minutes; oral: 30-60 minutes. |
| Duration of Action | Analgesic/antipyretic effects: 4-6 hours. Duration may be shorter with IV administration due to rapid distribution. |
| Molecular Weight | 151.16 |
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-60 mL/min: no adjustment; for GFR <30 mL/min: extend interval to every 8 hours; maximum 3 g per day. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated. |
| Pediatric use | For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous. |
| Geriatric use | No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity. |
| 1st trimester | Limited human data; animal studies show no evidence of teratogenicity. Use only if clearly needed. |
| 2nd trimester | Generally considered safe; no known association with malformations. |
| 3rd trimester | Use with caution near term; may cause neonatal hepatic toxicity at high doses. |
Clinical note
Comprehensive clinical and safety monograph for INJECTAPAP (INJECTAPAP).
| Placental transfer | Acetaminophen crosses the placenta readily; fetal concentrations similar to maternal levels. |
| Breastfeeding | Acetaminophen is excreted into breast milk in low concentrations (less than 2% of maternal dose). Considered compatible with breastfeeding; avoid high doses or prolonged use. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity. |
| Fetal Monitoring | Monitor maternal liver function tests (ALT, AST) in cases of prolonged use or overdose. Fetal monitoring via ultrasound for growth restriction if chronic high-dose use. No specific fetal monitoring required for standard doses. |
| Fertility Effects | No known adverse effects on fertility. Acetaminophen has not been shown to impair male or female fertility at therapeutic doses. |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
| Serious Effects |
Hypersensitivity to acetaminophenSevere hepatic impairment (Child-Pugh class C)
| Precautions | Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment, Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis, Hypersensitivity reactions, Use caution in patients with G6PD deficiency, Avoid use with other acetaminophen-containing products |
| Food/Dietary | No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy. |
| Clinical Pearls | Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration. |
| Patient Advice | Do not take more than the recommended dose. Overdose can cause severe liver damage. · Inform your healthcare provider if you have liver disease or drink alcohol regularly. · Check other medications for acetaminophen to avoid double dosing. · Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain). · This medication is administered by intravenous infusion; do not attempt self-administration. |
Loading safety data…